BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36927895)

  • 1. [Pharmacologic Therapy for Bone Metastases-Current Strategies and Future Directions].
    Suzuki T; Sekine I
    Gan To Kagaku Ryoho; 2023 Mar; 50(3):299-303. PubMed ID: 36927895
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Denosumab: benefits of RANK ligand inhibition in cancer patients.
    Lipton A; Jacobs I
    Curr Opin Support Palliat Care; 2011 Sep; 5(3):258-64. PubMed ID: 21826000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Examination of the mechanisms of osteolysis in patients with metastatic breast cancer.
    Trinkaus M; Ooi WS; Amir E; Popovic S; Kalina M; Kahn H; Singh G; Gainford MC; Clemons M
    Oncol Rep; 2009 May; 21(5):1153-9. PubMed ID: 19360288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intervention with the Bone-Associated Tumor Vicious Cycle through Dual-Protein Therapeutics for Treatment of Skeletal-Related Events and Bone Metastases.
    Niu Y; Yang H; Yu Z; Gao C; Ji S; Yan J; Han L; Huo Q; Xu M; Liu Y
    ACS Nano; 2022 Feb; 16(2):2209-2223. PubMed ID: 35077154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical development of anti-RANKL therapies for treatment and prevention of bone metastasis.
    Lipton A; Goessl C
    Bone; 2011 Jan; 48(1):96-9. PubMed ID: 20950721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond.
    Deligiorgi MV; Panayiotidis MI; Griniatsos J; Trafalis DT
    Clin Exp Metastasis; 2020 Feb; 37(1):13-30. PubMed ID: 31578655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of the bone marrow microenvironment in multiple myeloma.
    Roodman GD
    J Bone Miner Res; 2002 Nov; 17(11):1921-5. PubMed ID: 12412796
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
    Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
    Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment and prevention of bone complications from prostate cancer.
    Lee RJ; Saylor PJ; Smith MR
    Bone; 2011 Jan; 48(1):88-95. PubMed ID: 20621630
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Encounter of cancer cells with bone. Treatment of bone metastases from breast cancer].
    Taguchi T
    Clin Calcium; 2011 Mar; 21(3):429-38. PubMed ID: 21358065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer metastasis to the bone: mechanisms of bone loss.
    Chen YC; Sosnoski DM; Mastro AM
    Breast Cancer Res; 2010; 12(6):215. PubMed ID: 21176175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates as treatment of bone metastases.
    Holen I; Coleman RE
    Curr Pharm Des; 2010; 16(11):1262-71. PubMed ID: 20166976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenesis and Treatment of Myeloma-Related Bone Disease.
    Gau YC; Yeh TJ; Hsu CM; Hsiao SY; Hsiao HH
    Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328533
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment.
    Criscitiello C; Viale G; Gelao L; Esposito A; De Laurentiis M; De Placido S; Santangelo M; Goldhirsch A; Curigliano G
    Cancer Treat Rev; 2015 Feb; 41(2):61-8. PubMed ID: 25499997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Denosumab for the treatment of bone disease in solid tumors and multiple myeloma.
    Yee AJ; Raje NS
    Future Oncol; 2018 Feb; 14(3):195-203. PubMed ID: 29052442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular pathways: osteoclast-dependent and osteoclast-independent roles of the RANKL/RANK/OPG pathway in tumorigenesis and metastasis.
    Dougall WC
    Clin Cancer Res; 2012 Jan; 18(2):326-35. PubMed ID: 22031096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nuclear factor-kappa B ligand and osteoprotegerin levels in serum and gingival crevicular fluid in patients with bone metastases treated with zoledronic acid.
    Inanc M; Kaynar L; Enhos S; Pala C; Karaca H; Berk V; Ozkan M; Sıvgın S; Eser B; Cetin M; Elmali F
    Med Oncol; 2014 Mar; 31(3):837. PubMed ID: 24448976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pathophysiology of bone metastases in urologic carcinomas].
    Sauer G; Barth TF; Möller P
    Urologe A; 2007 Aug; 46(8):888-90. PubMed ID: 17632696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Denosumab in patients with cancer-a surgical strike against the osteoclast.
    Brown JE; Coleman RE
    Nat Rev Clin Oncol; 2012 Jan; 9(2):110-8. PubMed ID: 22231759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone metastasis in breast cancer: the story of RANK-ligand.
    Azim HA; Kamal NS; Azim HA
    J Egypt Natl Canc Inst; 2012 Sep; 24(3):107-14. PubMed ID: 22929916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.